Table 2.
Planned and actual dosing regimens and injections (FAS)
| Treatment-naïve (n = 201) | Previously treated (n = 73) | Overall (n = 274) | |
|---|---|---|---|
| Planned dosing regimen | |||
| T&E from initial treatment | 51 (25.4) | 8 (11.0) | 59 (21.5) |
| 3 initial monthly injections, then T&E | 84 (41.8) | 31 (42.5) | 115 (42.0) |
| 3 initial monthly injections, then every other month | 5 (2.5) | 4 (5.5) | 9 (3.3) |
| Treat until dry, then T&E | 12 (6.0) | 19 (26.0) | 31 (11.3) |
| Treat until dry, then PRN | 20 (10.0) | 2 (2.7) | 22 (8.0) |
| PRN from initial treatment | 17 (8.5) | 6 (8.2) | 23 (8.4) |
| Other | 12 (6.0) | 3 (4.1) | 15 (5.5) |
| Reported dosing regimena | |||
| T&E from initial treatment | 43 (21.4) | 7 (9.6) | 50 (18.3) |
| 3 initial monthly injections, then T&E | 40 (19.9) | 25 (34.3) | 65 (23.7) |
| 3 initial monthly injections, then every other month | 9 (4.5) | 2 (2.7) | 11 (4.0) |
| Treat until dry, then T&E | 12 (6.0) | 18 (24.7) | 30 (11.0) |
| Treat until dry, then PRN | 51 (25.4) | 5 (6.9) | 56 (20.4) |
| PRN from initial treatment | 21 (10.5) | 8 (11.0) | 29 (10.6) |
| 3 initial monthly injections not completed | 7 (3.5) | 4 (5.5) | 11 (4.0) |
| Other | 18 (9.0) | 4 (5.5) | 22 (8.0) |
| IVT-AFL injections by month 6 (mean ± SD) | 3.1 ± 0.9 | 3.6 ± 1.3 | 3.2 ± 1.1 |
| IVT-AFL injections by month 12 (mean ± SD) | 4.2 ± 1.9 | 5.2 ± 2.7 | 4.4 ± 2.2 |
| ≥ 3 injections within 3 months | 127 (63.2) | 43 (58.9) | 170 (62.0) |
| ≥ 7 injections within 12 months | 24 (11.9) | 23 (31.5) | 47 (17.2) |
Data are n (%) unless otherwise stated
FAS full analysis set, IVT-AFL intravitreal aflibercept, PRN pro re nata, SD standard deviation, T&E treat and extend
aAs reported by the investigator(s)